Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Australian Clinical Labs Ltd ( (AU:ACL) ).
Macquarie Group Limited and a wide range of its controlled entities have notified Australian Clinical Labs that they have ceased to be a substantial holder in the company. The filing, made under Australian substantial holding rules, indicates a change in Macquarie’s voting interest and association structure, signaling a reduced institutional presence in ACL’s register that may slightly alter the company’s shareholder profile but does not directly affect day-to-day operations.
The notice lists Macquarie Group, Macquarie Bank, Macquarie Investment Services and various affiliated investment and holding vehicles across multiple jurisdictions as entities involved in the change. This reshaping of holdings reflects internal portfolio or structuring adjustments within Macquarie’s global network of investment entities, and will primarily be of interest to investors tracking shifts in major shareholdings and institutional support for Australian Clinical Labs.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.20 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd is an Australian healthcare company operating in the pathology and diagnostic testing industry. It provides clinical laboratory services, supporting medical practitioners and healthcare providers with diagnostic information used in patient care and medical decision-making.
Average Trading Volume: 862,207
Technical Sentiment Signal: Sell
Current Market Cap: A$360.3M
For a thorough assessment of ACL stock, go to TipRanks’ Stock Analysis page.